Atropos Health Earns Spot on Prestigious NY Digital Health 100 List

NEW YORK, NY – February 03, 2026 – Atropos Health, a company at the forefront of generating medical evidence from real-world data, has been named to the 2026 New York Digital Health 100 (DH100). The annual recognition, published by Digital Health New York (DHNY), honors the most innovative and high-impact digital health startups in the New York region, placing Atropos Health among an elite group of companies transforming the healthcare industry.

The inclusion highlights the growing importance of real-world evidence (RWE) in modern medicine and validates Atropos Health's role in accelerating data-driven decision-making for both healthcare providers and life science organizations. The award is announced alongside the 2026 New York Healthcare Innovation Report, which analyzes the trends and market dynamics shaping one of the world's most vibrant digital health ecosystems.

Powering Precision Medicine with Real-World Evidence

Atropos Health has distinguished itself through its unique platform, GENEVA OS®, the "operating system for rapid healthcare evidence." This system operates across a federated network of de-identified patient data, allowing clinicians and researchers to ask complex questions and receive reliable, evidence-based answers in a fraction of the time required by traditional research methods. This capability is crucial for closing the "evidence gaps" that often exist between clinical trials and real-world patient care.

"Atropos Health is proud to be part of the DH100 list as we continue to drive the adoption of real-world evidence for advancing precision medicine,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “Our work is helping healthcare systems and life sciences organizations make faster, more informed decisions about clinical care, drug development and discovery that ultimately improves patient outcomes.”

The company's recent launch of Commercial Analytics for life sciences further solidifies its innovative edge. This solution leverages ChatRWD®, a generative AI-powered tool that allows users to query vast datasets using natural language. Commercial and brand leaders can generate high-quality, brand-specific insights in seconds, complete with the underlying data, accelerating strategic decisions across research, development, and medical affairs. This technology directly addresses the need for speed and accuracy in a competitive pharmaceutical market.

A Market Shift from Experimentation to Execution

The DH100 recognition signifies more than just technological novelty; it points to a broader market maturation within digital health. The industry is moving past a phase of speculative pilots and into an era where scalable, sustainable business models are paramount.

“The breadth and depth of companies named to this year’s DH100 reflect a clear market shift from experimentation to execution,” said Bunny Ellerin, co-founder and CEO of DHNY. “These companies are scaling solutions that improve outcomes while building enduring businesses, demonstrating how innovation at the intersection of care delivery, data, and trust is shaping the next generation of healthcare leaders.”

Atropos Health exemplifies this shift. Its platform is not a theoretical concept but a deployed solution that provides tangible value to healthcare systems and life science companies. The DH100 selection process is rigorous, evaluating companies on leadership, funding, revenue, market fit, and differentiated offerings. Qualifying for the list indicates a company has demonstrated a clear path to commercial viability and impact, a crucial milestone for any startup in the competitive health-tech space. This year's list includes 48 new companies, highlighting the continuous influx of mature innovation into the ecosystem.

The Surging Demand for Data-Driven Healthcare

The recognition of Atropos Health comes as the market for real-world evidence solutions experiences explosive growth. Driven by regulatory acceptance, the push for personalized medicine, and intense pressure to control the soaring costs of drug development, RWE is becoming indispensable. The global RWE solutions market, valued at just over two billion dollars in 2023, is projected by some analysts to surge to over $7.6 billion by 2028.

Regulatory bodies like the U.S. Food and Drug Administration (FDA) are increasingly using RWE to monitor post-market safety and make regulatory decisions about drug effectiveness and labeling expansions. This provides a powerful incentive for life science companies to invest in robust RWE capabilities. Atropos Health's platform directly serves this need by offering a transparent and rapid way to generate evidence that can stand up to scientific and regulatory scrutiny. By turning vast pools of existing clinical data into actionable insights, RWE platforms help answer critical questions about how treatments perform in diverse, real-world patient populations that are often underrepresented in traditional clinical trials.

New York's Rise as a Global Digital Health Hub

Atropos Health's success is both a product of and a contributor to New York's thriving digital health ecosystem. The region has cultivated a fertile ground for health-tech innovation, combining a dense network of world-class academic medical centers and hospitals with a resilient and rebounding investment landscape. In 2024, venture funding for the sector soared to $4.0 billion, a 60% increase over the previous year, with late-stage deals commanding the lion's share of capital.

This environment fosters the kind of collaboration and access to talent that allows companies like Atropos Health to develop and scale their technologies effectively. Organizations like DHNY are instrumental in this growth, creating a connected community that shares ideas and showcases the city's leadership in healthcare innovation. The DH100 list itself serves as a beacon, attracting further investment and talent to the region. As digital health evolves from fragmented point solutions to more integrated systems for proactive, personalized care, companies on the DH100 list are poised to lead the charge, building the foundational infrastructure for the future of medicine.